Anti-CEACAM5 antibody and application thereof
A high-affinity anti-CEACAM5 nanobody integrated into a CAR-T cell receptor addresses the specificity and efficacy challenges of CEACAM5-targeted therapies, achieving effective tumor cell killing in gastric and pancreatic cancers.
Patent Information
- Application Number
- CN202411191000.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-28
AI Technical Summary
Current CAR-T cell therapies targeting CEACAM5 for solid tumors face challenges in specificity and efficacy due to the unique expression pattern of CEACAM5 in normal and tumor cells, limiting their therapeutic potential.
Development of a high-affinity anti-CEACAM5 antibody, specifically a nanobody (VHH) with defined CDR sequences, integrated into a chimeric antigen receptor (CAR) for T cells, enabling targeted killing of CEACAM5-positive tumor cells.
The anti-CEACAM5 CAR-T cells demonstrate efficient cytokine secretion and tumor cell killing, particularly against CEACAM5-positive gastric and pancreatic cancer cells, indicating potential for effective immunotherapy.
Smart Images

Figure BDA0005015092110000111 
Figure BDA0005015092110000131 
Figure HDA0005015092120000011
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of biomedicine, and in particular to an anti-CEACAM5 antibody and uses thereof. Background Art
[0002] Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), also known as CEA or CD66e, is the first member of the CEACAMs family. CEACAM5 was originally discovered in colon cancer and embryonic tissue (see: Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965 Sep 1; 122(3): 467-81.). It was later confirmed to be widely present in digestive system tumors of endodermal origin, such as gastric cancer, liver cancer, pancreatic cancer, and colon cancer. It is also elevated in the serum of breast cancer, lung cancer, and other malignant tumors. It is a broad-spectrum tumor marker (see: Han ZW, Lyv ZW, Cui B, et al. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs. 2020 Dec; 38(6): 1888-1898.).
[0003] CEACAM5 belongs to the immunoglobulin (Ig) superfamily and is membrane-bound via glycosylphosphatidylinositol (GPI). It possesses seven extracellular immunoglobulin-like domains, including a variable IgV-like domain (N domain) and six IgC-like domains. Furthermore, a 34-amino acid signal peptide precedes the Ig domain. The human CEACAM5 gene is located on chromosome 19q13.2 and is approximately 21 kb long, consisting of nine exons and three noncoding exons. The CEACAM5 protein consists of 642 amino acids (molecular weight approximately 70 kDa) and has 28 potential N-linked glycosylation sites. One CEACAM5 protein molecule contains 24-26 asparagine-linked sugar chains, with a final molecular weight of approximately 180 kDa (see: Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013 Dec; 32(3-4): 643-71.).
[0004] CEACAM5 expression begins in the early stages of embryonic and fetal development (9-14 weeks) and continues to be expressed in certain cells. In normal adult tissues, CEACAM5 is primarily found in colonic columnar epithelium and goblet cells, particularly in the upper third of the crypts and on the free luminal surface. It is also found in the stomach, tongue, esophagus, cervix, sweat glands, and prostate (see: S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999 Apr; 9(2): 67-81.). Interestingly, the expression of CEACAM5 in normal epithelial cells of the lung and gastrointestinal tract is limited to the apical surface of the epithelial cell membrane facing the lumen, making it impossible for immune cells to recognize it. When a tumor occurs, CEACAM5 in the luminal epithelial cells loses its apical polarity, thereby entering the capillaries and increasing the level of serum soluble CEACAM5 (see: Han ZW, Lyv ZW, Cui B, et al. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs. 2020 Dec; 38(6): 1888-1898.). Therefore, the unique localization pattern of CEACAM5 makes it a potential target for related antigens in cancer immunotherapy.
[0005] Adoptive immune cell therapy is considered a promising anti-tumor treatment. T cells expressing CAR transgenes can bind to tumor antigens through antigen-antibody recognition, thereby eliminating cancer cells. These CAR-T cells can directly recognize tumor cells, unrestricted by antigen processing and MHC. Currently, CAR-T therapy has achieved promising results in hematologic malignancies, and researchers are conducting further research in solid tumors by identifying a variety of tumor-associated antigens.
[0006] Due to its high expression and unique expression pattern in various tumor cells, CEACAM5 has become a popular target. A report on a phase I clinical trial for CEACAM5+ colon cancer (NCT02349724) indicated that patients with metastatic, recurrent, and refractory colon cancer were well tolerated by intravenous infusion of CEACAM5 CAR-T, even at high doses, and researchers observed a certain therapeutic effect in most patients (see: Zhang C, Wang Z, Yang Z, et al. Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers. Mol Ther. 2017 May 3; 25(5): 1248-1258.). In addition, Steven C. Katz et al. treated six patients with CEACAM5+ liver metastases by infusing CEACAM5 CAR-T through the hepatic artery (NCT01373047). The results showed that these patients tolerated the therapy well and did not experience severe cytokine release syndrome or neurotoxicity (see: Katz SC, Hardaway J, Prince E, et al. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internalradiation therapy for CEA+ liver metastases. Cancer Gene Ther. 2020 May; 27(5): 341-355.). These results support that CEACAM5, as an autoantigen with a strict luminal expression pattern, can safely become a target for CAR-T cell therapy, thereby producing a certain therapeutic effect on solid tumors.
[0007] In summary, CEACAM5 can be used as a target for tumor therapy, and providing an anti-CEACAM5 antibody with high specificity and affinity is of great significance for the treatment of malignant tumors. Summary of the Invention
[0008] In view of the above-mentioned shortcomings of the prior art, the object of the present invention is to provide an anti-CEACAM5 antibody and use thereof to solve the problems in the prior art.
[0009] To achieve the above objectives and other related objectives, the present invention provides an anti-CEACAM5 antibody, characterized in that the anti-CEACAM5 antibody comprises a heavy chain variable region, and the anti-CEACAM5 antibody has one or more of the following technical features:
[0010] <1> The heavy chain variable region includes CDR-H1 with the amino acid sequence shown in SEQ ID No. 1;
[0011] <2> The heavy chain variable region includes CDR-H2 with the amino acid sequence shown in SEQ ID No. 2;
[0012] <3> The heavy chain variable region includes CDR-H3 whose amino acid sequence is shown in SEQ ID No. 3.
[0013] The present invention also provides an isolated polypeptide comprising a transmembrane domain, an intracellular domain and an extracellular domain, wherein the extracellular domain comprises the anti-CEACAM5 antibody.
[0014] The present invention also provides an isolated polynucleotide encoding the anti-CEACAM5 antibody or the polypeptide.
[0015] The present invention also provides a nucleic acid construct comprising the isolated polynucleotide encoding the gene.
[0016] The present invention also provides a lentivirus, which is formed by viral packaging of the nucleic acid construct.
[0017] The present invention also provides a lentiviral vector system, which includes the nucleic acid construct and a helper plasmid or a host cell.
[0018] The present invention also provides a chimeric antigen receptor immune cell, wherein the chimeric antigen receptor immune cell expresses the membrane-bound isolated polypeptide.
[0019] As described above, the anti-CEACAM5 antibody and its use of the present invention have the following beneficial effects:
[0020] (1) The present invention immunizes unimmunized alpacas with CEACAM5 recombinant protein and cells overexpressing CEACAM5 to construct a phage-displayed nanobody library. Antibodies against CEACAM5 are screened based on the phage-displayed nanobody library. The obtained nanobodies can specifically bind to the CEACAM5 antigen with good affinity.
[0021] (2) The anti-CEACAM5 nanobody provided by the present invention has a high affinity. It is used as an antigen binding domain to construct a chimeric antigen receptor, and the chimeric antigen receptor is used to prepare CAR-T cells. The CAR-T cells have killing activity against CEACAM5-positive tumor cells, and after co-culture with CEACAM5-positive cells, they efficiently secrete the cytokine IFN-γ. The nanobody can be effectively used in immunotherapy and is of great significance for the development of tumor treatment drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1 This is a diagram showing the FACS detection results of the anti-CEACAM5 nanobody recognizing the CEACAM5 antigen in Example 3;
[0023] Figure 2 This is a graph showing the EC50 test results of the anti-CEACAM5 nanobody binding to the CEACAM5 antigen in Example 4;
[0024] Figure 3 This is the plasmid map of the chimeric antigen receptor lentiviral vector targeting CEACAM5 in Example 5;
[0025] Figure 4 Schematic diagram of the chimeric antigen receptor structure expressing CEACAM5 in Example 5;
[0026] Figure 5 Graph showing the flow cytometry results of chimeric antigen receptor expression rates on T lymphocytes in Example 8;
[0027] Figure 6 This is a graph showing the killing effect of CAR-T cells on CEACAM5-negative human embryonic kidney cells 293T in Example 9;
[0028] Figure 7 This is a graph showing the killing effect of CAR-T cells on CEACAM5-positive human gastric cancer cells N87-CEACAM5 in Example 9;
[0029] Figure 8 This is a graph showing the killing effect of CAR-T cells on CEACAM5-positive human orthotopic pancreatic adenocarcinoma cells BxPC3 in Example 9;
[0030] Figure 9 This is a bar graph of IFN-γ secretion by CAR-T cells in Example 10. DETAILED DESCRIPTION
[0031] The present invention provides an anti-CEACAM5 antibody A031, wherein the anti-CEACAM5 antibody comprises a heavy chain variable region and has one or more of the following technical features:
[0032] <1> The heavy chain variable region includes CDR-H1 with the amino acid sequence shown in SEQ ID No. 1;
[0033] <2> The heavy chain variable region includes CDR-H2 with the amino acid sequence shown in SEQ ID No. 2;
[0034] <3> The heavy chain variable region includes CDR-H3 with the amino acid sequence shown in SEQ ID No. 3;
[0035] GRTFSNYAYA (SEQ ID No. 1)
[0036] ISRSGDST (SEQ ID No. 2)
[0037] AAVLTDYERAYYRPTEYKY (SEQ ID No. 3).
[0038] The numbering and definition schemes were based on the IMGT method for annotating CDR and FR regions.
[0039] CDRs (complementarity determining regions) generally refer to regions within an antibody that are spatially complementary to antigenic determinants. The variability within an antibody is typically not evenly distributed throughout the variable region. The heavy chain variable region of a monoclonal antibody typically has three hypervariable regions (HVRs). These regions are spatially complementary to antigenic determinants, and are therefore also known as complementarity determining regions (CDRs). The heavy chain variable region typically includes three CDRs: HCDR1, HCDR2, and HCDR3.
[0040] In certain embodiments of the present invention, the complementarity determining region of the heavy chain variable region of the anti-CEACAM5 antibody comprises CDR-H1 having an amino acid sequence as shown in SEQ ID No. 1, CDR-H2 having an amino acid sequence as shown in SEQ ID No. 2, and CDR-H3 having an amino acid sequence as shown in SEQ ID No. 3.
[0041] The anti-CEACAM5 antibody is an antibody fragment and / or a monoclonal antibody.
[0042] "Antibody fragments" comprise a portion of an intact antibody, preferably comprising its antigen binding or variable region. For example, antibody fragments include nanobodies (VHH), single-chain antibodies (scFv), Fab, Fab', F(ab') or F(ab')2.
[0043] In the present invention, an unimmunized alpaca is immunized with CEACAM5 recombinant protein and a cell line overexpressing CEACAM5, and a phage-displayed nanoantibody library is constructed. CEACAM5 antibodies are screened based on the phage-displayed nanoantibody library to obtain monoclonal antibodies that can specifically bind to the CEACAM5 antigen.
[0044] In certain embodiments of the present invention, the anti-CEACAM5 antibody is a nanobody (Nb), i.e., a heavy chain single-domain antibody (VHH). Nanobodies contain only a heavy chain variable region (VHH) and CH2 and CH3 regions. Compared to other antibodies, nanobodies naturally lack light chains. Nanobody crystals are approximately 2.5 nm in diameter and 4 nm in length, representing the smallest naturally occurring fragment capable of binding to an antigen. The anti-CEACAM5 antibody of the present invention comprises only the heavy chain variable region, possesses high affinity and specificity, can efficiently target the CEACAM5 antigen, has a simple structure, is easy to prepare, and has important application value in the preparation of drugs targeting CEACAM5.
[0045] In certain embodiments of the present invention, the heavy chain variable region may further include a framework region, and the framework region may be located between the complementary determining regions or at both ends of the complementary determining regions. In certain specific embodiments of the present invention, the sequence of the framework region is a human monoclonal antibody variable region, or a framework region sequence of a murine monoclonal antibody variable region that is substituted, deleted, or added with one or more (specifically, 1-50, 1-30, 1-20, 1-10, 1-5, or 1-3) amino acids to obtain a framework region sequence, and the framework region sequence and the framework region sequence of the human monoclonal antibody variable region sequence may have 80%, 85%, 90%, 93%, 95%, 97%, or 99% or more homology.
[0046] In certain embodiments of the present invention, the heavy chain variable region further comprises a framework region, including framework regions FR1 to FR4, wherein the amino acid sequence of the framework regions FR1 to FR4 is selected from any of the sequences shown in SEQ ID Nos. 4 to 7.
[0047] Preferably, the amino acid sequence of FR1 is as shown in SEQ ID No. 4: EVQVQESGGGLVQAGDSLRLSCAAS (SEQ ID No. 4).
[0048] Preferably, the amino acid sequence of FR2 is as shown in SEQ ID No. 5: MGWFRQAPGKEREFVGA (SEQ ID No. 5)
[0049] Preferably, the amino acid sequence of FR3 is as shown in SEQ ID No.6: YFADFVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYC (SEQ ID No.6)
[0050] Preferably, the amino acid sequence of FR4 is as shown in SEQ ID No.7: WGQGTQVTVSS (SEQ ID No.7)
[0051] In certain embodiments of the present invention, the anti-CEACAM5 antibody is codenamed VHH-A031 or anti-CEACAM5-A031, and the heavy chain variable region of the anti-CEACAM5 antibody comprises a CDR-H1 with an amino acid sequence as shown in SEQ ID No. 1, a CDR-H2 with an amino acid sequence as shown in SEQ ID No. 2, a CDR-H3 with an amino acid sequence as shown in SEQ ID No. 3, and framework regions FR1 to FR4 with amino acid sequences as shown in SEQ ID Nos. 4 to 7.
[0052] Preferably, the amino acid sequence of the heavy chain variable region is shown as SEQ ID No.8.
[0053] EVQVQESGGGLVQAGDSLRLSCAASGRTFSNYAYAMGWFRQAPGKEREFVGAISRSG DSTYFADFVKGRFTISRDNAKSTVYLQMNSLKPEDTAVYYCAAVLTDYERAYYRPTEYKY WGQGTQVTVSS(SEQ ID No.8)
[0054] In certain embodiments of the present invention, the anti-CEACAM5 antibody is obtained by screening from a phage antibody library, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID No. 9:
[0055] GAGGTCCAAGTGCAAGAGAGCGGGGGGGCCTGGTCCAAGCTGGCGATAGCCTGAGACTGAGCTGCGCCGCTAGCGGCAGAACCTTCAGCAACTACGCCTACGCCATGGGCTGGTTCAGACAAGCCCCCGGCAAGGAGAGAGTTCGTGGGCGCCATCAGCAGAAGCGGCGACAGCACCTACTTCGCCGACTT CGTGAAGGGCAGATTCACCATCAGCAGAGACAACGCCAAGAGCACCGTGTACCTGCAGATGAACAGCCTGAAGCCCGAGGACACCGCCGTGTACTACTGCGCCGCCGTGCTGACCGACTACGAGAGAGCCTACTACAGACCCACCGAGTACAAGTACTGGGGCCAAGGCACCCAAGTGACCGTGAGCAGC(SEQ ID No.9)
[0056] Another aspect of the present invention provides an isolated polynucleotide encoding the anti-CEACAM5 antibody.
[0057] In certain embodiments of the present invention, the sequence of the polynucleotide is shown as SEQ ID No.9.
[0058] Another aspect of the present invention provides use of the anti-CEACAM5 antibody in preparing or screening therapeutic drugs, or in preparing diagnostic drugs.
[0059] The therapeutic drug may be a drug that uses the CEACAM5 antigen as a target, binds to or acts on the CEACAM5 antigen, and thereby treats and / or prevents the indicated disease.
[0060] In certain embodiments of the present invention, the therapeutic drug may be a tumor therapeutic drug. The tumor is a tumor that expresses CEACAM5. The tumor therapeutic drug may be a drug that targets the CEACAM5 antigen on the functional surface of tumor cells, binds to or acts on the CEACAM5 antigen, and thereby treats and / or prevents the tumor. The tumor may be a CEACAM5-positive tumor, such as colorectal cancer, pancreatic cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, gastric cancer, or gallbladder cancer.
[0061] In certain embodiments of the present invention, the therapeutic agent is a chimeric antigen receptor cell.
[0062] The chimeric antigen receptor cell therapy drug generally includes a chimeric antigen receptor cell, and the chimeric antigen receptor cell can be a chimeric antigen receptor T cell, a chimeric antigen receptor NK cell, etc. The chimeric antigen receptor T cell generally includes a T lymphocyte, which also includes a chimeric antigen receptor. The chimeric antigen receptor NK cell generally includes an NK cell, which also includes a chimeric antigen receptor. The chimeric antigen receptor includes a transmembrane domain, an intracellular domain, and an extracellular domain. In certain embodiments of the present invention, the extracellular domain includes the anti-CEACAM5 antibody, that is, the chimeric antigen receptor cell can express the anti-CEACAM5 antibody on the cell surface, thereby guiding the cell to act on cells expressing the CEACAM5 antigen (e.g., tumor cells). The action on cells expressing the CEACAM5 antigen can be killing cells expressing the CEACAM5 antigen, etc.
[0063] The diagnostic drug specifically refers to a reagent that targets the target CEACAM5 antigen and uses the CEACAM5 antigen as a biomarker for diagnosis.
[0064] Another aspect of the present invention provides an isolated polypeptide comprising a transmembrane domain, an intracellular domain and an extracellular domain, wherein the extracellular domain comprises the anti-CEACAM5 antibody.
[0065] In certain embodiments of the present invention, the polypeptide is a chimeric antigen receptor. In the present invention, the anti-CEACAM5 antibody is used to construct a chimeric antigen receptor, which can efficiently target CEACAM5.
[0066] In certain embodiments of the present invention, the transmembrane domain can be selected from any one or more transmembrane domains of CD8α transmembrane region, CD28 transmembrane region, DAP 10 transmembrane region, etc.
[0067] For another example, the sequence of CD8α can be referenced to NM_001145873, the sequence of CD28 can be referenced to NM_006139, and the sequence of DAP10 can be referenced to NM_014266.
[0068] In certain embodiments of the present invention, the intracellular domain may include a signal transduction domain.
[0069] The signal transduction domain includes an immunoreceptor tyrosine-based activation motif. The immunoreceptor tyrosine-based activation motif can be selected from CD3ζ.
[0070] Preferably, the signal transduction domain further comprises a co-stimulatory molecule. For example, the co-stimulatory molecule can be selected from any one or a combination of at least two protein molecules such as 4-1BB, CD28, OX40, ICOS, DAP 10. For another example, the amino acid sequence of 4-1BB can include the following:
[0071] KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL(SEQ ID No.12)
[0072] For another example, the sequence of 4-1BB can be referenced to NM_001561, the sequence of CD28 can be referenced to NM_006139, the sequence of OX40 can be referenced to NM_003327, the sequence of ICOS can be referenced to NM_012092, the sequence of CD3 zeta can be referenced to NM_198053, and the sequence of DAP10 can be referenced to NM_014266.
[0073] In a specific embodiment of the present invention, the intracellular domain includes 4-1BB and CD3 zeta in sequence from the N-terminus to the C-terminus.
[0074] In certain embodiments of the present invention, the extracellular domain may include a signal peptide, an anti-CEACAM5 antibody, and a hinge region.
[0075] In certain embodiments of the present invention, the signal peptide comprises a CD8α signal peptide.
[0076] In certain embodiments of the present invention, the hinge region is selected from the CD8α hinge region.
[0077] In certain embodiments of the present invention, the polypeptide comprises, from N-terminus to C-terminus, a CD8α signal peptide, the anti-CEACAM5 antibody, a transmembrane domain, and an intracellular domain.
[0078] In some specific embodiments of the present invention, the polypeptide includes, from N-terminus to C-terminus, a CD8α signal peptide, an anti-CEACAM5 nanobody, a CD8α hinge region, a CD8α transmembrane region, a co-stimulatory molecule, and CD3 zeta.
[0079] In some specific embodiments of the present invention, the polypeptide includes, from N-terminus to C-terminus, a CD8α signal peptide, an anti-CEACAM5 nanobody, a CD8α hinge region, a CD8α transmembrane region, 4-1BB, and CD3 zeta.
[0080] In certain embodiments of the present invention, the polynucleotide sequence encoding the isolated polypeptide is shown in SEQ ID No. 21:
[0081]
[0082] The present invention also provides a nucleic acid construct comprising a polynucleotide encoding the isolated polypeptide.
[0083] The nucleic acid construct can be a lentiviral vector, a retroviral vector, or an adeno-associated viral vector. Taking a lentiviral vector as an example, the lentiviral vector comprises a vector backbone, i.e., an empty vector, and an expression cassette. In other words, the nucleic acid construct is a vector containing the gene encoding the chimeric antigen receptor.
[0084] The term "nucleic acid construct" or "vector" refers to a nucleic acid fragment or polynucleotide fragment used to introduce or transfer one or more nucleic acids or one or more polynucleotides into a target cell or tissue. Typically, a vector is used to introduce exogenous DNA into another cell or tissue. A vector may contain bacterial resistance genes for growth in bacteria and a promoter for expression of a protein of interest in an organism. DNA can be produced in vitro by PCR or any other suitable technique or techniques known to those skilled in the art.
[0085] The term "expression cassette" refers to a sequence that has the potential to encode a protein.
[0086] The present invention also provides a lentivirus, wherein the lentivirus is formed by viral packaging of the nucleic acid construct and contains the nucleic acid construct.
[0087] The present invention also provides a lentiviral vector system, characterized in that the lentiviral vector system comprises the nucleic acid construct and a helper plasmid.
[0088] Furthermore, the helper plasmid encodes one or more nucleotide sequences of gag, pol, Rev, VSVg protein and other necessary viral packaging component nucleotide sequences. The helper plasmids can be purchased commercially, for example, Addgene catalog numbers 14887 and 8454.
[0089] Furthermore, the lentiviral vector system further includes a host cell, which can be a cell for producing lentivirus, for example, a mammalian cell, specifically a 293T cell.
[0090] The lentivirus can be obtained by transfecting host cells with the nucleic acid construct and helper plasmid in the lentiviral vector system. The host cells can be mammalian cells.
[0091] Another aspect of the present invention provides a chimeric antigen receptor immune cell, wherein the chimeric antigen receptor immune cell expresses the isolated polypeptide bound to a membrane.
[0092] Preferably, the chimeric antigen receptor immune cell comprises the nucleic acid construct and / or the lentivirus.
[0093] The immune cells are selected from any one of T lymphocytes, B lymphocytes, NK cells, mast cells or macrophages.
[0094] In another specific embodiment of the present invention, the chimeric antigen receptor immune cell is a T lymphocyte.
[0095] The T lymphocytes can typically express the polypeptide, which can typically bind to the CEACAM5 antigen, and more specifically can bind to the CEACAM5 antigen via the extracellular domain of the anti-CEACAM5 antibody. When the polypeptide binds to the CEACAM5 antigen, the T lymphocytes can typically be activated and / or stimulated to proliferate. In certain embodiments of the present invention, the T lymphocytes, i.e., chimeric antigen receptor T cells, can express the anti-CEACAM5 antibody on their surface, thereby guiding the T lymphocytes to act on cells expressing the CEACAM5 antigen (e.g., tumor cells), and the action can include killing cells expressing the CEACAM5 antigen.
[0096] In another specific embodiment of the present invention, the chimeric antigen receptor immune cell is a NK cell.
[0097] The NK cells can typically express the polypeptide and can typically bind to the CEACAM5 antigen, more specifically, can bind to the CEACAM5 antigen via the extracellular domain of the anti-CEACAM5 antibody. When the polypeptide binds to the antigen, the NK cells can typically be activated and / or stimulated to proliferate. In certain embodiments of the present invention, the NK cells, i.e., chimeric antigen receptor NK cells, can express the anti-CEACAM5 antibody on their surface, thereby guiding the NK cells to act on cells expressing the CEACAM5 antigen (e.g., tumor cells), and the action can include killing cells expressing the CEACAM5 antigen.
[0098] Another aspect of the present invention provides the use of the isolated polypeptide, isolated polynucleotide, nucleic acid construct, lentivirus, chimeric antigen receptor immune cell in preparing or screening therapeutic drugs, or in preparing diagnostic drugs.
[0099] The therapeutic or diagnostic drug may be a drug that uses the CEACAM5 antigen as a target, binds to or acts on the CEACAM5 antigen, and thereby treats and / or prevents the indicated disease.
[0100] In certain embodiments of the present invention, the therapeutic drug may be a tumor therapeutic drug. The tumor therapeutic drug may target the CEACAM5 antigen functionally expressed on the surface of tumor cells, bind to or act on the CEACAM5 antigen, and thereby treat and / or prevent tumors. The tumor may be a CEACAM5-positive tumor, such as gastric cancer, lung cancer, pancreatic cancer, or intestinal cancer.
[0101] The present invention provides a pharmaceutical composition comprising the chimeric antigen receptor immune cell and / or the anti-CEACAM5 antibody and / or the isolated polypeptide.
[0102] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.
[0103] "Pharmaceutically acceptable" means that the drugs do not produce adverse, allergic or other untoward reactions when properly administered to animals or humans.
[0104] A "pharmaceutically acceptable carrier or excipient" should be compatible with the active ingredient, meaning it can be blended with the active ingredient without significantly reducing the drug's efficacy under normal circumstances. Pharmaceutically acceptable carriers or excipients are selected from any one or a combination of at least two of surfactants, disintegrants, coating materials, excipients, solubilizers, diluents, pH adjusters, binders, wetting agents, colorants, emulsifiers, antibacterial agents, solubilizers, osmotic pressure regulators, fillers, antioxidants, or buffers. Specific examples include sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium methylcellulose, ethylcellulose, and methylcellulose; tragacanth powder; malt; gelatin; talc; solid lubricants such as stearic acid and magnesium stearate; calcium sulfate; vegetable oils such as peanut oil, cottonseed oil, sesame oil, olive oil, corn oil, and cocoa butter; polyols such as propylene glycol, glycerol, sorbitol, mannitol, and polyethylene glycol; alginic acid; emulsifiers such as Tween; wetting agents such as sodium lauryl sulfate; coloring agents; flavoring agents; tableting agents, stabilizers; antioxidants; preservatives; pyrogen-free water; isotonic saline solution; and phosphate buffers, etc. These substances are used as needed to help stabilize the formulation or to help improve the activity or its bioavailability or to produce an acceptable taste or smell in the case of oral administration.
[0105] The following describes the embodiments of the present invention through specific examples. Those skilled in the art will readily understand the other advantages and benefits of the present invention from the disclosure herein. The present invention may also be implemented or applied through various other specific embodiments, and the details in this specification may be modified or altered based on different viewpoints and applications without departing from the spirit of the present invention.
[0106] Before further describing the specific embodiments of the present invention, it should be understood that the scope of protection of the present invention is not limited to the specific specific embodiments described below; it should also be understood that the terms used in the examples of the present invention are for describing specific specific embodiments rather than for limiting the scope of protection of the present invention; in the present specification and claims, unless otherwise expressly stated herein, the singular forms "a", "an" and "the" include plural forms.
[0107] When the embodiments provide numerical ranges, it should be understood that, unless otherwise specified in the present invention, both endpoints of each numerical range and any numerical value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in the present invention have the same meaning as those generally understood by those skilled in the art. In addition to the specific methods, equipment, and materials used in the embodiments, according to the understanding of the prior art by those skilled in the art and the description of the present invention, any methods, equipment, and materials of the prior art similar or equivalent to the methods, equipment, and materials described in the embodiments of the present invention may also be used to implement the present invention.
[0108] If no specific techniques or conditions are specified in the examples, the experiments were carried out according to the techniques or conditions described in the literature in the field or according to the product instructions. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0109] Example 1
[0110] In this example, a phage nanobody library was constructed and panned, and preliminary screening was performed using ELISA. The specific steps are as follows:
[0111] (1) Construction of phage nanoantibody library
[0112] Alpacas were immunized with human CEACAM5 recombinant protein and a cell line overexpressing CEACAM5. After serum titers were determined by ELISA, peripheral blood was drawn. Lymphocytes were isolated, and total RNA was extracted and reverse-transcribed into cDNA. The VHH gene was then amplified using nested PCR. The VHH gene was inserted into the PhD-dAb-1 vector and electroporated into SS320 competent cells. After amplification, phage was isolated and purified to obtain an antibody library. The concentration was adjusted, and the cells were aliquoted and stored frozen at -80°C until further use.
[0113] (2) Screening of phage nanoantibody library
[0114] First, the phage antibody library was screened in two rounds, liquid phase and solid phase, respectively. The screened antibody library was then incubated with AsPC-1, Colo205, and SNU5 cells for negative screening, and then incubated with AsPC-1-CEACAM5 and Colo205-CEACAM5 / GFP cells for positive screening.
[0115] The phage library was isolated and purified for the next round of ELISA screening. After enrichment, the obtained phage was used as a template to amplify the VHH region and perform second-generation sequencing to obtain an anti-CEACAM5 nanobody with an amino acid sequence as shown in SE1 ID NO.21, named VHH-A031.
[0116] Example 2
[0117] In order to further identify the antibody, this example performed VHH Fc nanobody expression, purification, and antibody affinity determination.
[0118] The obtained antibody quality test results are shown in Table 1.
[0119] Table 1
[0120]
[0121] Example 3
[0122] In this example, the anti-CEACAM5 nanobody of Example 1 was subjected to flow cytometry.
[0123] HGC-27 and HGC-27-CEACAM5 cells (prepared in Example 7) were mixed with purified anti-CEACAM5 nanobody and incubated on ice for 30 min. They were then incubated with APC-labeled anti-human IgG antibody for 30 min. Flow cytometry was used to detect the cells. Figure 1 As shown, it is shown that the anti-CEACAM5 nanobody of the present invention can recognize the CEACAM5 antigen on the cell surface.
[0124] Example 4
[0125] In this example, the anti-CEACAM5 nanobody of Example 1 was subjected to ELISA detection to determine the EC50 value of its binding to the CEACAM5 protein.
[0126] First, wash two clean ELISA plates with PBS, discard the PBS, and pat dry on absorbent paper. Dilute the Human CEACAM5-His (acro, cat# CE5-H5226) tag antigen to 1 μg / mL in PBS. Add 100 μL of CEACAM5-His tag antigen to each well of one plate. Seal the plates and place them in a 4°C refrigerator overnight for coating.
[0127] After overnight, remove the coated ELISA plate from the refrigerator, discard the liquid, and add 300 μL of PBS to each well. Discard the supernatant and pat dry on absorbent paper. Add 300 μL of 1× NAP blocking solution to each well, incubate at room temperature for 1 hour, discard the supernatant, and pat dry on absorbent paper. Dilute the primary antibody to 4 μg / mL in 1× NAP and perform a four-fold serial dilution series for a total of 11 concentrations, adding 50 μL to each well. Add an equal volume of 1× NAP to the blank wells as a control, seal the plate with sealing film, incubate at room temperature for 1 hour, discard the supernatant, and pat dry on absorbent paper. Wash each well by adding 300 μL of TBST, soak for 30 seconds, discard the liquid, pat dry on absorbent paper, and repeat this wash 4-5 times. Dilute the secondary antibody (0.4 μg / mL, Goat Anti-Human IgG HRP H&L, Cat#ab6858) in 1× NAP and add 50 μL to each reaction well. Incubate at room temperature for 1 hour. Discard the supernatant and wash with 300 μL of TBST per well. Soak for 30 seconds, then discard the liquid and pat dry on absorbent paper. Repeat this wash 4–5 times. Add 50 μL of HRP substrate to each well and incubate at room temperature in the dark for 5–30 minutes. Terminate the substrate reaction by adding 50 μL of 1N HCl to each well. Measure absorbance at 450 nm using a microplate reader.
[0128] The results are as follows Figure 2 As shown, the EC50 of CEACAM5 nanobody VHH-A031 binding to CEACAM5 protein is about 0.0150 μg / mL, which is at the nanomolar level, indicating that VHH-A031 can bind to CEACAM5 protein well.
[0129] Example 5
[0130] In this example, a lentiviral vector expressing a chimeric antigen receptor targeting CEACAM5 (CEACAM5 CAR) was prepared.
[0131] First, a lentiviral vector HD SIN03 anti-CEACAM5VHH-41BBz carrying a CEACAM5 CAR chimeric antigen receptor was constructed. The vector map is shown in Figure 2. Figure 3 A schematic diagram of the chimeric antigen receptor is shown in Figure 4 As shown, it includes CD8α signal peptide, anti-CEACAM5 nanobody (anti-CEACAM5 VHH), CD8α hinge region, transmembrane region, co-stimulatory molecules and immunoreceptor tyrosine activation motif (CD3ζ).
[0132] Among them, the amino acid sequence of the signal peptide (SEQ ID NO.10) is:
[0133] MALPVTALLLPLALLLHAARP.
[0134] The amino acid sequence of anti-CEACAM5 VHH is shown in SEQ ID NO.8.
[0135] The amino acid sequence of the CD8α hinge and transmembrane regions (SEQ ID NO. 11) is:
[0136] TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYC.
[0137] The amino acid sequence of the 4-1BB co-stimulatory molecule (SEQ ID NO.12) is:
[0138] KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL.
[0139] The amino acid sequence of CD3ζ (SEQ ID NO. 13) is:
[0140] RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPQRRKNPQ EGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR.
[0141] The specific preparation method is as follows:
[0142] (1) Prepare the PCR reaction system according to Table 2 (the reagents in the table are from TOYOBO Inc.) to amplify each anti-CEACAM5 nanobody fragment. The reaction is carried out according to the PCR program shown in Table 3. The primer sequences are:
[0143] CEACAM5-A031-F(SEQ ID NO.14):
[0144] CTGCCGCTGGCCTTGCTGCTCCACGCCGCCAGGCCGGAGGTCCAAGTGCAAGAGAG.
[0145] CEACAM5-A031-R(SEQ ID NO.15):
[0146] GCGCTGGCGTCGTGGTGCTGCTCACGGTCACTTGG.
[0147] Table 2
[0148] Reagents Volume (μL) 10×PCR Buffer 5 2mM dNTP 5 <![CDATA[25mM MgSO4]]> 3 10 μM upstream primer 2 10 μM downstream primer 2 Template DNA (cDNA clone) 2 Sterile deionized water (PCR grade water) 30 KOD-Plus-Neo High-Fidelity PCR Enzyme 1
[0149] Table 3
[0150]
[0151] After the reaction, the PCR products were subjected to 1% agarose gel electrophoresis, and fragments of about 400 bp were recovered and quantified by UV absorption;
[0152] (2) Prepare the PCR reaction system according to Table 4. Add the CD8α signal peptide before the amplified product obtained in step (1). Perform the reaction according to the PCR program shown in Table 3. The primers are:
[0153] BamH-CD8αsig-F (SEQ ID NO.16):
[0154] GCTGCAGGTCGACTCTAGAGGATCCCGCCACCATGGCCTTACCAGTGACCGCCTTGCTCCTGCCGCTGGCCTTGC.
[0155] CEACAM5-A031-R(SEQ ID NO.15):
[0156] GCGCTGGCGTCGTGGTGCTGCTCACGGTCACTTGG.
[0157] Table 4
[0158] Reagents Volume (μL) 10×PCR Buffer 5 2mM dNTP 5 25mM MgSO4 3 10 μM upstream primer 2 10 μM downstream primer 2 Template DNA (VHH fragment PCR reaction solution) 2 Sterile deionized water (PCR grade water) 30 KOD-Plus-Neo High-Fidelity PCR Enzyme 1
[0159] After the reaction, the PCR products were subjected to 1% agarose gel electrophoresis, and the fragments of about 490 bp were recovered and quantified by UV absorption;
[0160] (3) Prepare the PCR reaction system according to Table 5. After the preparation, perform the PCR reaction according to Table 3 to amplify the CD8αhinge-TM-41BB-CD3Z fragment using the following primers:
[0161] CD8αH-F (SEQ ID NO. 17): ACCACGACGCCAGCGCCGCGAC.
[0162] Vector-R (SEQ ID NO. 18): TCGATAAGCTTGATATCG.
[0163] Table 5
[0164] Reagents Volume (μL) 10×PCR Buffer 5 2mM dNTP 5 25mM MgSO4 3 10 μM upstream primer CD8αH-F 2 10 μM downstream primer Vector-R 2 Template DNA (HD CEACAM5 CAR) 2 Sterile deionized water (PCR grade water) 30 KOD-Plus-Neo High-Fidelity PCR Enzyme 1
[0165] After PCR, 1% agarose gel electrophoresis was performed to recover the fragment of about 680 bp and quantify it by UV absorption method;
[0166] (4) 25 μg of laboratory-constructed HD SIN03 GUCY2C A3-41BBz plasmid was double-digested with BamHI and EcoRI, reacted in a 37°C water bath for 1 h, and the vector was recovered;
[0167] The two fragments recovered above were ligated to the vector backbone using recombinase. The recombination reaction system was shown in Table 6. After preparation, the reaction was carried out in a water bath at 37°C for 0.5 h and then transformed into Escherichia coli Stbl3 competent cells according to conventional methods.
[0168] Table 6
[0169] Reagents Usage HD CEACAM5 CAR skeleton 154.2ng CD8α singal CEACAM5 VHH 10ng CD8αhinge-TM-41BB-CD3Z 13.6ng 5×CE Buffer 2.4 μL Exnase MultiS 1.2 μL Sterile deionized water (PCR grade water) Make up to 12 μL
[0170] Single clones were selected from the solid culture medium for sequencing and identification, and the results were consistent with expectations. The sequencing primer sequences are as follows:
[0171] LV-F2 (SEQ ID NO. 19): TCTTGGTTCATTCTCAAGCCTC.
[0172] LV-R (SEQ ID NO. 20): GCAACATAGTTAAGAATACC.
[0173] Example 6
[0174] In this example, the lentiviral vector HD SIN03 anti-CEACAM5 VHH-41BBz prepared in Example 5 was packaged, concentrated, and titered, including the following steps:
[0175] (1) Lentiviral packaging
[0176] 293T cells were seeded at an appropriate concentration in a 15 cm dish and cultured overnight at 37°C in 5% CO2 to prepare virus packaging. The culture medium was DMEM supplemented with 10% fetal bovine serum. 14.5 μg of the lentiviral vector, HD SIN03 anti-CEACAM5VHH-41BBz, 16.7 μg of the helper plasmid pMDLg-RRE (Addgene, 12251), 16.7 μg of the helper plasmid pRSV-REV (Addgene, 12253), and 6.5 μg of the envelope plasmid VSVg (Addgene, 8454) were dissolved in 2 mL of serum-free DMEM and mixed thoroughly.
[0177] Dissolve 163.2 μg PEI (1 μg / μL) in 2 mL of serum-free DMEM medium, vortex at 1000 rpm for 5 seconds, and incubate at 25°C for 5 minutes. Add the PEI mixture to the DNA mixture, mix gently, and incubate at 25°C for 20 minutes to form a transfection complex. Then, add 4 mL of the transfection complex dropwise to 18 mL of DMEM medium containing 293T cells. After 6 hours, replace the medium with fresh medium. After 48 hours, collect the viral supernatant.
[0178] (2) Lentiviral titer detection
[0179] 500 μL Jurkat (1×10 5 Cells were seeded into 24-well culture plates. 1 μL, 5 μL, and 25 μL of the collected viral supernatant were added to the cell suspension, and polybrene was added to a final concentration of 8 μg / mL. After incubation at 37°C, 5% CO₂ for 72 hours, the cells were centrifuged at 500 g for 5 minutes, the supernatant discarded, and the cells were resuspended in 100 μL of PBS plus 2% FBS. 0.5 μg of Rabbit Anti-Camelid VHH (iFluor488) antibody was added, and the cells were incubated on ice for 30 minutes. After washing once with flow cytometry buffer (PBS containing 2% FBS), the cells were resuspended in 300 μL of flow cytometry buffer, and infection efficiency was determined by flow cytometry. The titer was calculated using the following formula: Titer (TU / mL) = number of cells × positive rate / virus volume (mL). The viral titer was 1.08E+07 TU / mL according to the titer formula.
[0180] Example 7 Construction of overexpression cell lines
[0181] Lentivirus overexpressing CEACAM5 was obtained by co-transfection of CEACAM5-puro plasmid, pMGlg-RRE, pRSV-REV and VSVg plasmid, following the same steps as in Example 6;
[0182] Take 1×10 6 HGC-27 cells and N87 cells were seeded into 6-well plates, and 1 mL of the CEACAM5-puro lentivirus obtained above was added to obtain HGC-27-CEACAM5 and N87-CEACAM5 overexpressing CEACAM5 protein.
[0183] Example 8
[0184] This example uses the lentivirus prepared in Example 6 to transduce T lymphocytes, including the following steps:
[0185] (1) Human PBMCs were adjusted to a density of 1×10 using T cell culture medium (X-VIVO + 10% FBS + 300 U / mL IL-2). 6 / mL, and 1 / 100 volume of T Cell TransAct (commercial magnetic beads coupled to CD3 and CD28) was added for activation for 24 h;
[0186] (2) Collect activated T cells and adjust the cell density to 1×10 6 / mL, add lentivirus at a multiplicity of infection (MOI) of 10, and add polybrene to a final concentration of 8 μg / mL; culture overnight at 37°C in a 5% CO2 environment, replace with fresh medium, and passage every 3 days;
[0187] (3) 8 days after T cell infection, 3×10 5 The T cells were centrifuged at 4°C and 500g for 5 minutes, the supernatant was discarded, and the cells were washed once with flow cytometry buffer; 50 μL of buffer was added to resuspend the cells, 0.5 μg of Rabbit Anti-Camelid VHH (iFluor488) antibody was added, and the cells were incubated on ice for 30 minutes; after washing once with buffer, 300 μL of buffer was added to resuspend the cells;
[0188] Flow cytometry was used to detect the expression rate of chimeric antigen receptors on T lymphocytes. Figure 5 As shown, the infection efficiency of CAR-T cells in each group was 71.1%, 78.8% and 67.8%, respectively, indicating that CAR-T cells were successfully constructed.
[0189] Example 9
[0190] In this example, the in vitro toxicity experiment of CAR-T cells was performed, including the following steps:
[0191] (1) Target cell inoculation
[0192] 293T-GPF-luci(CEACAM5 - ), N87-GFP-luci-CEACAM5(CEACAM5 + ), and BxPC3-GFP-luci (CEACAM5 + ) as target cells, and the target cell concentration was adjusted to 2×10 5 / mL, 50 μL was inoculated into a white opaque 96-well plate;
[0193] (2) Effector cell inoculation
[0194] CAR-T cells targeting CEACAM5 and control T cells were used as effector cells and were added to 96-well plates at effector-target ratios of 0.3:1, 1:1, and 3:1;
[0195] (3) Each group has two replicate wells, and the experimental and control groups are as follows:
[0196] Experimental group: target cells + T / CAR-T; control group: only target cells were inoculated.
[0197] (5) Detection method:
[0198] After the effector cells and target cells were co-cultured for 18 h, 70 μL of Steady-Lumi TM Firefly luciferase reporter gene detection reagent (Biyuntian, catalog number: RG058M) was used for reaction for 5 min, and the bioluminescence signal was detected using a multifunctional microplate reader.
[0199] (5) The formula for calculating the killing efficiency of CAR-T cells is: killing efficiency % = (1-experimental group / control group) × 100%.
[0200] The results are as follows Figures 6 to 8 As shown, the CAR-T cells constructed in the present invention have no killing effect on CEACAM5-negative 293T cells, but have killing activity on CEACAM5-positive tumor cells, indicating that the CAR-T cells constructed in the present invention not only have efficient tumor killing ability but also have high specificity.
[0201] Example 10
[0202] In this example, the secretion of CAR-T cell factor IFN-γ was detected, and the kits used were Human IFN-γ ELISA Kit (Lianke Bio, catalog number: EK180-96).
[0203] 1. Cell culture supernatant
[0204] The cell culture with an effector-target ratio of 1:1 was centrifuged at 400 g for 10 min to remove the precipitate, and the supernatant was stored at -80°C until testing.
[0205] 2. Reagent Preparation
[0206] Before testing, return all reagents and samples to 25°C. If concentrated reagents crystallize, incubate at 37°C until all crystals dissolve. Prepare 1× wash solution and 1× detection buffer according to the instructions.
[0207] 3. Preparation of standards and samples
[0208] Standards: Use 5% FBS1640 medium to dilute the standard solution 2-fold, with a total of 8 dilution gradients, including zero concentration.
[0209] Sample: Dilute the sample using 5% FBS1640 medium according to the ratio.
[0210] 4. Detection steps
[0211] (1) Soaking the microplate: Add 300 μL of 1× wash solution and let it soak for 30 seconds. Discard the wash solution and pat the microplate dry on absorbent paper.
[0212] (2) Adding standard: add 100 μL of 2-fold serially diluted standard to the standard wells, and add 100 μL of standard dilution to the blank wells;
[0213] (3) Add sample: add 100 μL of cell culture supernatant to the sample well;
[0214] (4) Add detection antibody: add 50 μL of diluted detection antibody (1:100 dilution) to each well;
[0215] (5) Incubation: Seal the plate with a sealing film, shake at 300 rpm, and incubate at 25°C for 2 h;
[0216] (6) Washing: Discard the liquid and add 300 μL of washing solution to each well to wash the plate. Wash the plate 6 times. Pat the plate dry on absorbent paper after each wash.
[0217] (7) Enzyme incubation: Add 100 μL of diluted horseradish peroxidase-labeled streptavidin (1:100 dilution) to each well;
[0218] (8) Incubation: Seal the plate with a new sealing film, shake at 300 rpm, incubate at 25°C for 45 min, and wash;
[0219] (9) Add substrate for color development: Add 100 μL of color development substrate TMB to each well, protect from light, and incubate at 25°C for 20 min;
[0220] (10) Add stop solution: add 100 μL stop solution to each well;
[0221] (11) Detection reading: Within 30 minutes, dual-wavelength detection was performed using an enzyme-linked microplate reader to measure the OD value at the maximum absorption wavelength of 450 nm and the reference wavelength. The calibrated OD value was the measured value at 450 nm minus the measured value at the reference wavelength.
[0222] The results of IFN-γ secretion were Figure 9As shown, the spontaneous MOCK group (CAR-T cell alone) showed essentially no cytokine release; the CAR-T cell and 293T cell co-culture group also showed essentially no cytokine detection; and after co-culture with CEACAM5-positive target cells, the CAR-T cells secreted more than 500 pg / mL of IFN-γ. The CAR-T cells constructed in this invention release cytokines for CEACAM5-positive tumor cells, but show no significant cytokine secretion for CEACAM5-negative cells.
[0223] In summary, the anti-CEACAM5 nanoantibodies with high affinity screened and prepared by the present invention can efficiently bind to CEACAM5 specifically, and are used as antigen-binding domains to construct chimeric antigen receptors and CAR-T cells. The resulting CAR-T cells have obvious killing activity and specificity against CEACAM5-positive tumor cells, and can secrete tumor-killing cytokines, indicating that the nanoantibodies of the present invention can be effectively used in immunotherapy and are of great significance for the development of tumor treatment drugs.
[0224] The above examples are intended to illustrate the embodiments disclosed herein and are not to be construed as limiting the present invention. In addition, the various modifications listed herein and variations of the methods in the invention will be apparent to those skilled in the art without departing from the scope and spirit of the present invention. Although the present invention has been specifically described in conjunction with various specific preferred embodiments of the present invention, it should be understood that the present invention should not be limited to these specific embodiments. In fact, various modifications apparent to those skilled in the art as described above to obtain the invention should be included within the scope of the present invention.
Claims
1. An anti-CEACAM5 antibody, It is characterized in that The anti-CEACAM5 antibody comprises a heavy chain variable region, and the anti-CEACAM5 antibody has one or more of the following technical features; <1> The heavy chain variable region includes CDR-H1 with the amino acid sequence shown in SEQ ID No. 1; <2> The heavy chain variable region includes CDR-H2 with an amino acid sequence as shown in SEQ ID No. 2; <3> The heavy chain variable region includes CDR-H3 whose amino acid sequence is shown in SEQ ID No.
3.
2. The anti-CEACAM5 antibody according to claim 1, It is characterized in that The heavy chain variable region also includes a framework region, which includes framework regions FR1 to FR4. The amino acid sequences of the framework regions FR1 to FR4 are shown in SEQ ID Nos. 4 to 7.
3. The anti-CEACAM5 antibody according to claim 1, It is characterized in that The amino acid sequence of the heavy chain variable region is shown in SEQ ID No.
8.
4. The anti-CEACAM5 antibody according to claim 1, It is characterized in that The anti-CEACAM5 antibody is a nanobody.
5. Use of the anti-CEACAM5 antibody according to any one of claims 1 to 4 in the preparation or screening of tumor therapeutic drugs.
6. The use according to claim 5, It is characterized in that The tumor is a tumor that overexpresses CEACAM5; preferably, the tumor is selected from colorectal cancer, pancreatic cancer, breast cancer, bladder cancer, ovarian cancer, lung cancer, gastric cancer or gallbladder cancer; Preferably, the tumor therapeutic drug is a chimeric antigen receptor cell.
7. An isolated polypeptide, It is characterized in that The polypeptide comprises a transmembrane domain, an intracellular domain and an extracellular domain, and the extracellular domain comprises the anti-CEACAM5 antibody according to any one of claims 1 to 4.
8. The polypeptide according to claim 7, It is characterized in that Also includes any one or more of the following features: a) the polypeptide is a chimeric antigen receptor; b) the transmembrane domain is selected from any one or more of the CD8α transmembrane region, the CD28 transmembrane region, and the DAP 10 transmembrane region; c) the intracellular domain includes a signal transduction domain; preferably, the signal transduction domain includes an immunoreceptor tyrosine-based activation motif and a co-stimulatory molecule; more preferably, the immunoreceptor tyrosine-based activation motif is selected from CD3ζ; preferably, the co-stimulatory molecule is selected from any one of 4-1BB, CD28, OX40, ICOS, and DAP 10, or a combination of at least two thereof; d) the extracellular domain comprises a signal peptide, an anti-CEACAM5 antibody, and a hinge region; preferably, the signal peptide comprises a CD8α signal peptide; preferably, the hinge region is selected from a CD8α hinge region; e) The polypeptide includes, from N-terminus to C-terminus, a CD8α signal peptide, an anti-CEACAM5 antibody, a CD8α hinge region, a CD8α transmembrane region, a co-stimulatory molecule, and a CD3 zeta signal domain.
9. An isolated polynucleotide, It is characterized in that Encoding the anti-CEACAM5 antibody according to any one of claims 1 to 4 or the polypeptide according to any one of claims 7 to 8.
10. A nucleic acid construct, It is characterized in that Contains a polynucleotide encoding the isolated protein of claim 9.
11. The nucleic acid construct according to claim 10, It is characterized in that The nucleic acid construct is any one of a lentiviral vector, a retroviral vector or an adeno-associated viral vector.
12. A lentivirus, It is characterized in that The lentivirus is formed by viral packaging of the nucleic acid construct according to claim 10 or 11.
13. A lentiviral vector system, It is characterized in that The lentiviral vector system comprises the nucleic acid construct of claim 10 or 11 and a helper plasmid or a host cell.
14. A chimeric antigen receptor immune cell, It is characterized in that The chimeric antigen receptor immune cell expresses the membrane-bound isolated polypeptide according to any one of claims 7 to 8.
15. The chimeric antigen receptor immune cell according to claim 14, It is characterized in that The immune cell is selected from any one of T lymphocytes, B lymphocytes, NK cells, mast cells or macrophages.
16. Use of the isolated polypeptide according to any one of claims 7 to 8 or the chimeric antigen receptor immune cell according to any one of claims 14 to 15 in the preparation or screening of tumor therapeutic drugs.
17. The use according to claim 16, It is characterized in that The tumor is a tumor expressing CEACAM5; preferably, the tumor is selected from liver cancer, ovarian cancer, lung cancer, melanoma, gastric cancer or thyroid cancer.
18. A pharmaceutical composition, It is characterized in that The pharmaceutical composition comprises the chimeric antigen receptor immune cell according to any one of claims 14 to 15 and a pharmaceutically acceptable carrier or excipient.
Citation Information
Patent Citations
CEA (carcinoembryonic antigen) resistant nanomater antibody with high appetency and application
CN107880130A
Anti-mesothelin nano antibody with high affinity and application thereof
CN116063531A
Nanometer antibody targeting CEACAM5 as well as preparation method and application thereof
CN116178556A
Preparation method and application of CEACAM5 targeted CAR-T cell
CN116376920A
Antibody specifically bound to glycosylated ceacam5
WO2022267936A1
